DXCM
DexCom, Inc.
62.22
2 x 62.15
3 x 62.30
bid
ask
-
0.15
0.24%
3 @ 04:00 PM
63.30 +1.08 (1.74%)
Ytd -6.25%
1y -8.69%
60.57
day range
62.86
54.84
52 week range
89.53
Open 61.50 Prev Close 62.37 Low 60.57 High 62.86 Mkt Cap 24.27B
Vol 2.41M Avg Vol 5.04M EPS 2.09 P/E 29.77 Forward P/E 20.80
Beta 1.53 Short Ratio 3.89 Inst. Own 100.86% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 04-30 50-d Avg 69.40 200-d Avg 71.64 1yr Est 87.13
Earning
Date For Estimate Reported Surprise surprise %
2026-04-30 2026-03 0.47 N/A N/A N/A
2026-02-12 2025-12 0.65 0.68 0.03 4.62%
2025-10-30 2025-09 0.57 0.61 0.04 7.02%
2025-07-30 2025-06 0.45 0.48 0.03 6.67%
2025-05-01 2025-03 0.33 0.32 -0.01 -3.03%
2025-02-13 2024-12 0.5 0.45 -0.05 -10.00%
Upgrade / Downgrade
Date Firm Action From To
2026-03-11 Citigroup Upgrade Buy Buy
2026-03-09 BTIG Upgrade Buy Buy
2026-02-25 BTIG Upgrade Buy Buy
2026-02-17 Truist Securities Upgrade Buy Buy
2026-02-13 Canaccord Genuity Upgrade Buy Buy
2026-02-13 Barclays Upgrade Underweight Underweight
Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Insider Holder
Date Name Relation Quantity Description
2025-05-07 ALTMAN STEVEN R Director 63.67K Stock Gift
2026-03-15 BROWN MICHAEL JON Officer 112.90K Sale
2026-03-05 COLEMAN JON Officer 112.64K Stock Award(Grant)
2025-01-28 DOLAN MATTHEW VINCENT Officer 42.04K Sale
2025-08-14 FOLETTA MARK G Director 0.00 Sale
2026-03-05 LEACH JACOB STEVEN Chief Executive Officer 469.11K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Vanguard Group Inc 49.07M 3.05B 12.75%
2025-12-30 Blackrock Inc. 39.85M 2.48B 10.35%
2025-12-30 State Street Corporation 18.09M 1.13B 4.70%
2025-12-30 BAILLIE GIFFORD & CO 15.55M 967.68M 4.04%
2025-12-30 Geode Capital Management, LLC 11.01M 684.80M 2.86%
2025-12-30 Alliancebernstein L.P. 8.62M 536.59M 2.24%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 12.26M 763.07M 3.19%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 9.83M 611.83M 2.55%
2026-01-30 Invesco QQQ Trust, Series 1 8.49M 528.53M 2.21%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund 8.49M 528.18M 2.21%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Growth Index Fund 5.12M 318.52M 1.33%
2026-01-30 iShares Trust-iShares Core S&P 500 ETF 5.02M 312.27M 1.30%
Split
Split Date
4 : 1 2022-06-13
4 : 1 2022-06-10